
<DOC>
<DOCNO>WT02-B08-79</DOCNO>
<DOCOLDNO>IA072-000460-B044-419</DOCOLDNO>
<DOCHDR>
http://www.cinp.aust.com:80/mp.html 203.108.64.146 19970121030644 text/html 47573
HTTP/1.0 200 OK
Date: Tue, 21 Jan 1997 02:58:04 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 47401
Last-modified: Tue, 18 Jun 1996 07:20:06 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE></TITLE>
</HEAD>
<BODY BGCOLOR="#f2e2d6" ALINK="#ff0000">
<H5><CENTER><A HREF="index.htm"><BR>
<BR>
</A><A HREF="index.htm#anchor689408"><IMG SRC="files.gif/smanlog.gif" WIDTH=
"62" HEIGHT="57" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></A></CENTER>
</H5>
<H5><BR>
<BR>
XX TH C.I.N.P. CONGRESS<BR>
WORLD CONGRESS CENTRE MELBOURNE</H5>
<HR>
<H2>MONDAY JUNE 24, 1996</H2>
<HR>
<H4>ROOM CODES:</H4>
LA = LA TROBE THEATRE, H2 = HOWQUA 2, H3 = HOWQUA 3, O1 = OTWAY 1, <BR>
O2 = OTWAY 2, C1 = CORRYONG 1,<BR>
C2-5 = CORRYONG 2-5, JB = JOHN BATMAN THEATRE, B1 = BELLARINE 1, <BR>
B2 = BELLARINE 2, B3 = BELLARINE 3,<BR>
B4 = BELLARINE 4, B5 = BELLARINE 5, B7 = BELLARINE 7 
<H4>PRESENTATION CODES:</H4>
BW = BREAKFAST WORKSHOP, L = PLENARY LECTURE, P = POSTER PRESENTATION,<BR>
O = ORAL/FREE COMMUNICATION, S = SYMPOSIA<BR>
<BR>
<HR><B>DAY Monday TIME 0730 - 0830 <BR>
<BR>
ROOM LA</B><BR>
<BR>
SESSION HEADING Breakfast Workshop<BR>
Supported by an Educational Grant from Akzo Nobel<BR>
<BR>
BW-1 
<BLOCKQUOTE>Clinical Management of Depression:<BR>
Practical Issues</BLOCKQUOTE>
<BR>
<BR>
<HR><B>DAY Monday TIME 0830-0930<BR>
<BR>
ROOM JB</B><BR>
<BR>
SESSION HEADING Presidential Address<BR>
<BR>
L-1-1 Judd, Lewis L 
<BLOCKQUOTE>New Observations in the Life Course of Unipolar Major Depression:
<BR>
Risk Factors and Treatment Goals</BLOCKQUOTE>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM H2</B><BR>
<BR>
SESSION HEADING Addiction 1<BR>
<BR>
O-1-1 Elliot, Elizabeth E 
<BLOCKQUOTE>Radiotelemetry: A Model for Measuring<BR>
Precipitated and Spontaneous<BR>
Lorazepam Withdrawal</BLOCKQUOTE>
<BR>
O-1-2 Lazarevic, Katrina 
<BLOCKQUOTE>Alcholism and Liver Enzymes</BLOCKQUOTE>
<BR>
O-1-3 Humeniuk, Rachel E 
<BLOCKQUOTE>The Ambulatory Monitor - An Objective<BR>
Method of Alcohol Withdrawal<BR>
Assessment in Humans</BLOCKQUOTE>
<BR>
O-1-4 Kalyoncu, Ayhan O 
<BLOCKQUOTE>Double-Blind Comparative Trial With<BR>
Carbamazepine Vs Diazepam Treatment<BR>
of Alcohol Withdrawal</BLOCKQUOTE>
<BR>
O-1-5 De Vry, Jean M V 
<BLOCKQUOTE>Pharmacotherapy of Alcoholism:<BR>
Effects of Clinically Evaluated<BR>
Compounds in a Rat Model of<BR>
Alcoholism</BLOCKQUOTE>
<BR>
O-1-6 Strzelec, Jaroseaw S 
<BLOCKQUOTE>The Influence of Selected Quinolones<BR>
on Central Action of Ethyl Alcohol in<BR>
Laboratory Animals</BLOCKQUOTE>
<BR>
O-1-7 Ladewig, Dieter R 
<BLOCKQUOTE>Use of Benzodiazepines in Opiate<BR>
Addicted Patients - Results of an Inquiry in Basle</BLOCKQUOTE>
<BR>
O-1-8 Jones, Reese T 
<BLOCKQUOTE>Cannabis Withdrawal Syndrome:<BR>
Laboratory Artifact or Clinically Important?</BLOCKQUOTE>
<BR>
O-1-9 Parrott, Andrew C 
<BLOCKQUOTE>Cigarette Smoking and Mood: The<BR>
Psychological Processes Which Underlie Nicotine Addiction</BLOCKQUOTE>
<BR>
O-1-10 Nagata, Ken 
<BLOCKQUOTE>Effects of Cigarette Smoking on<BR>
Cerebral Circulation in Normal Adults</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM H3</B><BR>
<BR>
SESSION HEADING Pharmacokinetics<BR>
<BR>
O-2-1 Tsuang, Ming T 
<BLOCKQUOTE>Are Genetic Influences Shared Across<BR>
Drug Categories? Evidence From a Twin Study</BLOCKQUOTE>
<BR>
O-2-2 Ereshefsky, Larry E 
<BLOCKQUOTE>CYP2D6 Drug Interaction Potential of<BR>
Four SSRI's Using In Vivo Dextromethorphan</BLOCKQUOTE>
<BR>
O-2-3 Coutts, Ronald T 
<BLOCKQUOTE>Contributions of Cytochrome P450<BR>
Isozymes to Metabolic Pathways of Haloperidol</BLOCKQUOTE>
<BR>
O-2-4 Eyles, Darryl W 
<BLOCKQUOTE>Toxic Haloperidol Metabolites in Human Brain</BLOCKQUOTE>
<BR>
O-2-5 Fujimaki, Hideo 
<BLOCKQUOTE>Plasma Neuroleptic Level and Clinical<BR>
Effects of Nemonapride- Factors<BR>
Weakening the Correlation</BLOCKQUOTE>
<BR>
O-2-6 Mauri, Massino Carlo 
<BLOCKQUOTE>Plasma Levels of Clozapine and<BR>
Norclozapine in Chronic Schizophrenics</BLOCKQUOTE>
<BR>
O-2-7 McIntyre, Iain M 
<BLOCKQUOTE>Postmortem Concentrations of<BR>
Clozapine and Desmethylclozapine in<BR>
Two Coronial Cases</BLOCKQUOTE>
<BR>
O-2-8 Hartter, Sebastian 
<BLOCKQUOTE>Inhibition of Clomipramine Metabolism<BR>
By Fluvoxamine (In Vivo and In Vitro Data)</BLOCKQUOTE>
<BR>
O-2-9 Someya, Toshiyuki 
<BLOCKQUOTE>Plasma Concentrations of<BR>
Trans-10-Hydroxy Metabolites Have<BR>
Relation With Clinical Effects of<BR>
Amitriptyline in Depression</BLOCKQUOTE>
<BR>
O-2-10 Kumar, Vinod 
<BLOCKQUOTE>Plasma Levels of Sertraline and the Clinical Response</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM O1</B><BR>
<BR>
SESSION HEADING Psychogeriatrics<BR>
<BR>
O-3-1 Korner, Alex 
<BLOCKQUOTE>Prevalence of Depressive Symptoms in<BR>
the Elderly. A Community Study</BLOCKQUOTE>
<BR>
O-3-2 Moore, Brian P 
<BLOCKQUOTE>Biological Abnormalities in<BR>
Depression in the Elderly</BLOCKQUOTE>
<BR>
O-3-3 McWilliam, Christopher 
<BLOCKQUOTE>Outcome of Depression in Elderly<BR>
Patients Changed From Tricyclic and<BR>
Other Antidepressants to Fluoxetine</BLOCKQUOTE>
<BR>
O-3-4 Malsch, Ulrich 
<BLOCKQUOTE>Cardiac Tolerability of Trimipramine<BR>
in the Elderly</BLOCKQUOTE>
<BR>
O-3-5 Wallin, Anders P 
<BLOCKQUOTE>The Depression Anxiety Syndrome in Dementia</BLOCKQUOTE>
<BR>
O-3-6 Ohta, Tomoo 
<BLOCKQUOTE>Effects of Electroconvulsive Therapy<BR>
on Cognitive Function in Geriatric<BR>
Patients with Depression</BLOCKQUOTE>
<BR>
O-3-7 Finkel, Sanford I 
<BLOCKQUOTE>Managing Elderly Patients With<BR>
Psychotic and Behavioural<BR>
Disturbances in Dementia</BLOCKQUOTE>
<BR>
O-3-8 Ohayon, Maurice M 
<BLOCKQUOTE>Sleep and Psychotropic Drug<BR>
Consumption: Relationships With Aging</BLOCKQUOTE>
<BR>
O-3-9 Ratti, Emiliangelo 
<BLOCKQUOTE>Pharmacological Profile of GV150526A<BR>
a Novel Glycine Antagonist For Stroke</BLOCKQUOTE>
<BR>
O-3-10 Rutigliano, Giulio 
<BLOCKQUOTE>Is Paroxetine in Post-Stroke<BR>
Depression Useful?</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM C1</B><BR>
<BR>
SESSION HEADING Psychoimmunology<BR>
<BR>
O-4-1 Ravizza, Luigi 
<BLOCKQUOTE>Natural Killer Cell Activity and In<BR>
Vitro Responsiveness to<BR>
Glucocorticoids and Cytokines in the<BR>
Elderly and in Alzheimer's Disease</BLOCKQUOTE>
<BR>
O-4-2 Bennett, Barbara K 
<BLOCKQUOTE>Longitudinal Course of Immune Changes<BR>
in Severe Depression</BLOCKQUOTE>
<BR>
O-4-3 Sluzewska, Anna M 
<BLOCKQUOTE>The Effects of Potentiation With<BR>
Lithium of Antidepressant Drugs on<BR>
Immunological Indices in Refractory<BR>
Depression</BLOCKQUOTE>
<BR>
O-4-4 Muller, Norbert 
<BLOCKQUOTE>T-Cells and NK-Cells in<BR>
Schizophrenia: Comparison Before and<BR>
During Neuroleptic Therapy</BLOCKQUOTE>
<BR>
O-4-5 Miller, Carl 
<BLOCKQUOTE>Are Immunological Alterations in<BR>
Schizophrenia Due to<BR>
Psychopharmalogical Treatment?</BLOCKQUOTE>
<BR>
O-4-6 Xue, Bin 
<BLOCKQUOTE>Effect of Cadmium on Immune Function<BR>
and Lymphocyte Calcium Homeostasis</BLOCKQUOTE>
<BR>
O-4-7 Ravizza, Luigi <BR>
In Vitro and In Vivo Effects of 
<BLOCKQUOTE>Anxiety and Benzodiazepine on Immune Parameters and Lymphocyte<BR>
Benzodiazepine Receptor mRNA</BLOCKQUOTE>
<BR>
<HR>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM H2<BR>
<BR>
SESSION HEADING Bipolar Disorders<BR>
<BR>
O-5-1 Marneros, Andreas 
<BLOCKQUOTE>Bipolar Mixed Disorders</BLOCKQUOTE>
<BR>
O-5-2 Ellen, Steven R 
<BLOCKQUOTE>Mania Secondary to HIV Infection</BLOCKQUOTE>
<BR>
O-5-3 Gaszner, Peter 
<BLOCKQUOTE>Pharmacological Treatment of Mania<BR>
(The Use of Code-HD)</BLOCKQUOTE>
<BR>
O-5-4 Walker, Rowan G 
<BLOCKQUOTE>Renal Function after 20 Years of<BR>
Lithium</BLOCKQUOTE>
<BR>
O-5-5 Berk, Michael 
<BLOCKQUOTE>Superiority of Lithium over Verapamil<BR>
in Mania: A Randomised Controlled<BR>
Trial</BLOCKQUOTE>
<BR>
O-5-6 Ketter, Terence 
<BLOCKQUOTE>A Baseline Hypermetabolism May Predict<BR>
Carbamazepine Repsonse, and<BR>
Hypometabolism Nimodipine Response in<BR>
Mood Disorders</BLOCKQUOTE>
<BR>
O-5-7 Walsh, Anne 
<BLOCKQUOTE>GH &amp; PRL Response to Apomorphine in<BR>
Bipolar and Unipolar Depression</BLOCKQUOTE>
<BR>
O-5-8 Thakore, Jogin H 
<BLOCKQUOTE>D-Fenfluramine-Induced Prolactin<BR>
Release in Bipolar Mania</BLOCKQUOTE>
<BR>
O-5-9 Nathan, Pradeep J 
<BLOCKQUOTE>Factors Affecting Melatonin<BR>
Sensitivity to Light: Relevance for a<BR>
Putative Marker of Bipolar Affective<BR>
Disorder</BLOCKQUOTE>
<BR>
O-5-10 Rutigliano, Giulio 
<BLOCKQUOTE>Lithium Therapy: Some Consideration<BR>
About Safety</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM H3</B><BR>
<BR>
SESSION HEADING Children &amp; adolescents<BR>
<BR>
O-6-1 Martin, Graham D E 
<BLOCKQUOTE>The Treatment of Adolescent<BR>
Depression: Where is the Evidence?</BLOCKQUOTE>
<BR>
O-6-2 Chebykina, Tamara N 
<BLOCKQUOTE>Peculiarities of Depressive States in<BR>
Children</BLOCKQUOTE>
<BR>
O-6-3 Walter, Garry J 
<BLOCKQUOTE>The Use of Electroconvulsive Therapy<BR>
in Young People</BLOCKQUOTE>
<BR>
O-6-4 Alderman, Jeffrey 
<BLOCKQUOTE>Sertraline Treatment in Children and<BR>
Adolescents: Tolerability, Efficacy<BR>
and Pharmacokinetics</BLOCKQUOTE>
<BR>
O-6-5 Cosgrove, Finn 
<BLOCKQUOTE>Risperidone Added to Methylphenidate<BR>
in Attention Deficit Hyperactivity<BR>
Disorder</BLOCKQUOTE>
<BR>
O-6-6 Chustrak, Anatoly P 
<BLOCKQUOTE>Impact of Stress-Factors of Technical<BR>
Accident on Emotional Sphere of<BR>
Children</BLOCKQUOTE>
<BR>
O-6-7 Chebykin, Alexey Y 
<BLOCKQUOTE>Prophylactic of Emotional Stress in<BR>
Schoolchildren</BLOCKQUOTE>
<BR>
O-6-8 Min, Sung K 
<BLOCKQUOTE>Handedness and Behaviour Problems in<BR>
Children</BLOCKQUOTE>
<BR>
O-6-9 Lintsi, Mart 
<BLOCKQUOTE>Role of Body Build and Temperament in<BR>
Children Treated Because of Neurotic<BR>
Disorders</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM O1</B><BR>
<BR>
SESSION HEADING Women's health<BR>
<BR>
O-7-1 Lugo, Franco 
<BLOCKQUOTE>Eating Disorders and Diagnostic<BR>
Subtypes: Targeted Use of<BR>
Antidepressants</BLOCKQUOTE>
<BR>
O-7-2 Berk, Michael 
<BLOCKQUOTE>The Augmented Platelet Intracellular<BR>
Calcium Response to Serotonin in<BR>
Anorexia Nervosa but not Bulimia may<BR>
be due to Subsyndromal Depression</BLOCKQUOTE>
<BR>
O-7-3 de Zwaan, Martina 
<BLOCKQUOTE>Pain Sensitivity, Alexithymia, and<BR>
Depression in Patients With ED</BLOCKQUOTE>
<BR>
O-7-4 Sirota, Pinkhas 
<BLOCKQUOTE>Olfactory Sensitivity in Eating<BR>
Disorders</BLOCKQUOTE>
<BR>
O-7-5 Eriksson, Elias 
<BLOCKQUOTE>On the Possible Role of Testosterone<BR>
in Serotonin-Related Psychiatric<BR>
Disorders in Women</BLOCKQUOTE>
<BR>
O-7-6 Buist, Anne 
<BLOCKQUOTE>Antidepressants and Breastfeeding</BLOCKQUOTE>
<BR>
O-7-7 Rohde, Anke 
<BLOCKQUOTE>Postpartum Psychoses: Long-Term<BR>
Course and Outcome</BLOCKQUOTE>
<BR>
O-7-8 George, Thomas 
<BLOCKQUOTE>A Review of the Nosological Status<BR>
and Aetiological Theories of<BR>
Postpartum Psychosis</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM C1<BR>
</B><BR>
SESSION HEADING Miscellaneous: clinical<BR>
<BR>
O-8-1 Hoschl, Cyril 
<BLOCKQUOTE>Comparison of Undergraduate and<BR>
Postgraduate Psychiatric Training in<BR>
Eastern Europe</BLOCKQUOTE>
<BR>
O-8-2 Mann, Klaus 
<BLOCKQUOTE>Therapeutic Effect of Yohimbine in<BR>
Organic and Non-Organic Erectile<BR>
Dysfunction</BLOCKQUOTE>
<BR>
O-8-3 Nakamura, Jun 
<BLOCKQUOTE>Does Plasma Free-MHPG Increase in the<BR>
Delirous State?</BLOCKQUOTE>
<BR>
O-8-4 Samonina, Galina e 
<BLOCKQUOTE>Antiulcer Properties of Some Prolin<BR>
Containing Oligopeptides</BLOCKQUOTE>
<BR>
O-8-5 Molnar, Gabor 
<BLOCKQUOTE>Betahistine and Neuroplasticity in<BR>
Vertigo</BLOCKQUOTE>
<BR>
O-8-6 Khokhlov, Alexander L 
<BLOCKQUOTE>Treatment of Anxiety Disorders in<BR>
Rheumatic Heart Disease</BLOCKQUOTE>
<BR>
O-8-7 Grigoryeva, E A 
<BLOCKQUOTE>Mental Disorders in Rheumatic Heart<BR>
Disease</BLOCKQUOTE>
<BR>
O-8-8 Freed, Edgar D 
<BLOCKQUOTE>Peer Review System Accepted For Three<BR>
Year Hospital Accreditation</BLOCKQUOTE>
<BR>
O-8-9 Joubert, Andre F 
<BLOCKQUOTE>Epilepsy in Forensic Psychiatry</BLOCKQUOTE>
<BR>
O-8-10 Puri, Vishambhar H 
<BLOCKQUOTE>Further Studies With Marine Compound<BR>
NIO-50</BLOCKQUOTE>
<BR>
O-8-11 Healy, David 
<BLOCKQUOTE>Negative Priming in High Schizotypes,<BR>
Psychosis and After Ketamine</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM O2</B><BR>
<BR>
SESSION HEADING Combined SSRI/5-HT 1a antagonist therapy for the treatment
of<BR>
depressive illness<BR>
Chair: C Dourish (UK) Co-chair: P Blier (Canada)<BR>
<BR>
S-1-1 Deakin, John Francis W 
<BLOCKQUOTE>The Need For Faster and More<BR>
Effective Antidepressants</BLOCKQUOTE>
<BR>
S-1-2 Artigas, Francesc 
<BLOCKQUOTE>Augmentation of Antidepressant<BR>
Effects With 5-HT1A Antagonists.<BR>
Basic and Clinical Studies</BLOCKQUOTE>
<BR>
S-1-3 Dourish, Colin T 
<BLOCKQUOTE>The 5-HT1A Receptor Antagonist<BR>
Way-100635 Enhances the Behavioural<BR>
Effects of SSRIs</BLOCKQUOTE>
<BR>
S-1-4 Blier, Pierre 
<BLOCKQUOTE>Present and Future Tools To Improve<BR>
the Antidepressant Response Based on<BR>
the Differential Properties of 5-HT<BR>
Receptor Subtypes</BLOCKQUOTE>
<BR>
S-1-5 Charney, Dennis Double-blind Study on the Effect of 
<BLOCKQUOTE>Pindool Afddition to Accelerate the<BR>
Antidepressant Response</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM B1</B><BR>
<BR>
SESSION HEADING Partial dopamine agonists - clinical and brain imaging effects<BR>
Chair: S Potkin (USA)<BR>
<BR>
S-2-1 Carlsson, Arvid 
<BLOCKQUOTE>Stabilizing Action of Partial<BR>
Dopamine Receptor Agonists in<BR>
Psychosis</BLOCKQUOTE>
<BR>
S-2-2 Tamminga, Carol A 
<BLOCKQUOTE>The Development of (-)-3PPP as an<BR>
Antipsychotic Drug</BLOCKQUOTE>
<BR>
S-2-3 Potkin, Steven G 
<BLOCKQUOTE>Neuroimaging to Evaluate Atypical<BR>
Antipsychotic Compounds: An FDG PET<BR>
Study of SDZ MAR 327</BLOCKQUOTE>
<BR>
S-2-4 Meltzer, Leonard T 
<BLOCKQUOTE>Preclinical Pharmacology of Dopamine<BR>
Partial Agonists</BLOCKQUOTE>
<BR>
S-2-5 Toru, Michio 
<BLOCKQUOTE>Late Phase II Study of OPC-14597, A<BR>
Dopamine Autoreceptor Agonist in<BR>
Schizophrenic Patients</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM B2</B><BR>
<BR>
SESSION HEADING The relationship between depression and somatisation<BR>
Chair: C Altamura (Italy)<BR>
<BR>
S-3-1 Janca, Aleksandar 
<BLOCKQUOTE>Somatization Across Different<BR>
Psychopathological States</BLOCKQUOTE>
<BR>
S-3-2 Altamura, Carlo Alfredo 
<BLOCKQUOTE>Comorbidity Between Somatoform<BR>
Disorders and Depression</BLOCKQUOTE>
<BR>
S-3-3 Kasper, Siegfried 
<BLOCKQUOTE>Assessment of Somatic Symptoms in<BR>
Depression and Somatoform Disorders</BLOCKQUOTE>
<BR>
S-3-4 Potter, William Z 
<BLOCKQUOTE>Depression and Somatization: A<BR>
Neurochemical Link?</BLOCKQUOTE>
<BR>
S-3-5 Maes, Michael H 
<BLOCKQUOTE>Psychoimmunological and<BR>
Neuroendocrine Findings in Depression<BR>
and Somatization</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM B3</B><BR>
<BR>
SESSION HEADING Molecular pathophysiology of Alzheimer's disease - Part
1<BR>
Chair: C Masters (Australia)<BR>
<BR>
S-4-1 Masters, Colin L 
<BLOCKQUOTE>Multiple Amyloidogenic Pathways in<BR>
Alzheimer's Disease - Which is the<BR>
Therapeutic Target?</BLOCKQUOTE>
<BR>
S-4-2 Bush, A I 
<BLOCKQUOTE>Abnormal Homeostasis of pH and Zinc:<BR>
The Prelude for Cerebral AB Amyloid<BR>
Formation</BLOCKQUOTE>
<BR>
S-4-3 Wischik, C 
<BLOCKQUOTE>Phosphorylation Events Surrounding<BR>
Neurofibrillary Tangle Formation</BLOCKQUOTE>
<BR>
S-4-4 Unterbeck, 
<BLOCKQUOTE>A Pharmaceutical Research and<BR>
Development Activities in Alzheimer's<BR>
Disease</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM B4<BR>
</B><BR>
SESSION HEADING ECT: advances in basic and clinical research<BR>
Chair: B Lerer (Israel) Co-chair: H Sackheim (USA)<BR>
<BR>
S-5-1 Bolwig, Tom G NPY 
<BLOCKQUOTE>Increases in Rat Brain Following<BR>
Electroconvulsive Seizures: an Animal<BR>
Model for the Working Action of ECT</BLOCKQUOTE>
<BR>
S-5-2 Lerer, Bernard 
<BLOCKQUOTE>Genes and the Mechanism of Action of<BR>
ECT: Focus on 5-HT1A Receptors</BLOCKQUOTE>
<BR>
S-5-3 Nutt, David J 
<BLOCKQUOTE>Peripheral and Endocrine Measures of<BR>
ECT's Effects: Relation to Side<BR>
Effects and Outcome</BLOCKQUOTE>
<BR>
S-5-4 Sackeim, Harold A 
<BLOCKQUOTE>Medication Resistance, ECT Response<BR>
and Relapse Prevention</BLOCKQUOTE>
<BR>
S-5-5 Weiner, Richard D 
<BLOCKQUOTE>ECT: Relationships Among Therapeutic<BR>
Outcome, Amnesia, and EEG Response</BLOCKQUOTE>
<BR>
<B><HR>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM B5</B><BR>
<BR>
SESSION HEADING Molecular biology of serotonergic system and aggressive
behaviours<BR>
Chair: J Mann (USA) Co-chair: B Eichelman (USA)<BR>
<BR>
S-6-1 Eichelman, Burr S Preclinical Models of Aggressive 
<BLOCKQUOTE>Behaviour: The Role of Serotonin</BLOCKQUOTE>
<BR>
S-6-2 Raleigh, Michael J 
<BLOCKQUOTE>Individual Differences in 5-HT1 Receptors and Aggressive Behaviour
in<BR>
Monkeys</BLOCKQUOTE>
<BR>
S-6-3 Mann, John 
<BLOCKQUOTE>Molecular Genetics of SuicidalBehaviour</BLOCKQUOTE>
<BR>
S-6-4 Nelson, David L 
<BLOCKQUOTE>Serotonergic Targets for thePharmacotherapy of Aggression</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM B7</B><BR>
<BR>
SESSION HEADING Neuro AIDS I: animal models and mechanisms<BR>
Chair: S Koslow (USA) Co-chair: C Lyketsos (USA)<BR>
<BR>
S-7-1 Grant, Igor 
<BLOCKQUOTE>The Diagnosis, Course, Biological andNeuropathological Correlates
of HIV Neurocognitive Disorder</BLOCKQUOTE>
<BR>
S-7-2 Berman, Nancy E J 
<BLOCKQUOTE>Pathogenesis of the AIDS DementiaComplex in the SIV Model</BLOCKQUOTE>
<BR>
S-7-3 Bloom, Floyd E 
<BLOCKQUOTE>Animal Models for NeuroAIDS</BLOCKQUOTE>
<BR>
S-7-4 Vitkovic, Ljubisa 
<BLOCKQUOTE>Current Progress in Developing RodentModels of HIV/CNS Disease</BLOCKQUOTE>
<BR>
S-7-5 Lyman, William D Monocyte 
<BLOCKQUOTE>Transit Across theBlood-Brain Barrier in AIDS: A Role for Adhesion
Molecules and Chemokines</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM LA</B><BR>
<BR>
SESSION HEADING D2 Receptors in striatum - do D2 receptors mediate excitation
or<BR>
inhibition?<BR>
Chair: M Sasa (Japan) Co-chair: J Waddington (Ireland)<BR>
<BR>
S-8-1 Kitai, Stephen T 
<BLOCKQUOTE>State-Dependent Regulation of Neuronal Excitability By Dopamine</BLOCKQUOTE>
<BR>
S-8-2 White, Francis J 
<BLOCKQUOTE>Dopamine D2 Receptors in the Ventral Striatum: Multiple Effects
or Receptor Subtypes?</BLOCKQUOTE>
<BR>
S-8-3 Sasa, Masashi 
<BLOCKQUOTE>D2 Receptor Activation in Distinct Striatal Neurons in Comparison
With D3 Receptors</BLOCKQUOTE>
<BR>
S-8-4 Calabresi, Paolo 
<BLOCKQUOTE>D2 Dopamine Receptors in the Short and Long-Term Modulation
of Corticostriatal Transmission</BLOCKQUOTE>
<BR>
S-8-5 Kawaguchi, Yasuo 
<BLOCKQUOTE>Cholinergic and GABAergicInterneurons in the Striatum</BLOCKQUOTE>
<BR>
S-8-6 Waddington, John L 
<BLOCKQUOTE>Do 'D2-Like' Dopamine Receptors Mediate Neuronal Excitation
Or Inhibition: Some<BR>
Functional-Behavioural Implications</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1000-1230<BR>
<BR>
ROOM JB</B><BR>
<BR>
SESSION HEADING Advances in the treatment of schizophrenia: into the 21st
century<BR>
Sponsored by Zeneca Pharmaceuticals<BR>
Chair: D Copolov (Australia)<BR>
<BR>
S-9-1 Copolov, David L 
<BLOCKQUOTE>Developing New Antipsychotic Drugs and Treatment Strategies:
An Overview</BLOCKQUOTE>
<BR>
S-9-2 Weinberger, Daniel R 
<BLOCKQUOTE>The Effects of New Antipsychotic Drugs on the Circuitry Dysfunction
of Schizophrenia</BLOCKQUOTE>
<BR>
S-9-3 Fibiger, Hans C 
<BLOCKQUOTE>Immediate Early Gene Expression and the Mechanisms of Action
of Atypical Antipsychotics</BLOCKQUOTE>
<BR>
S-9-4 Kerwin, Robert W 
<BLOCKQUOTE>Pharmacological Genetic Association Studies and Clozapine Response</BLOCKQUOTE>
<BR>
S-9-5 Lieberman, Jeffrey A 
<BLOCKQUOTE>Treatment and Consequences of Relapse in Schizophrenia</BLOCKQUOTE>
<BR>
S-9-6 Fleischhacker, Wolfgang W 
<BLOCKQUOTE>Contemporary and Anticipated Approaches to the Reduction of
Antipsychotic Induced Side Effects</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM O2</B><BR>
<BR>
SESSION HEADING Mixed anxiety depression, adjustment disorder with anxious
mood,<BR>
sub-threshold anxious depressive disorders'<BR>
Chair: P Boyer (France) Co-chair: A Altamura<BR>
<BR>
S-10-1 Maier, Wolfgang 
<BLOCKQUOTE>Subthreshold Anxiety and Depression Disorders: Prevalence Rates
and Needs for Treatment</BLOCKQUOTE>
<BR>
S-10-2 Tyrer, P<BR>
<BR>
S-10-3 Boyer, Patrice 
<BLOCKQUOTE>Efficacy of Pharmacological Treatment in Short Term Anxiety</BLOCKQUOTE>
<BR>
S-10-4 Weiller, Emmanuelle 
<BLOCKQUOTE>Social Phobia: Defining Thresholdsfor Treatment Intervention</BLOCKQUOTE>
<BR>
S-10-5 Bisserbe, Jean-Claude 
<BLOCKQUOTE>Psychotropic Drugs Use in Patients with Anxious or Depressive
Disorders Versus Subthreshold Syndromes</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1330-1600</B><BR>
<BR>
ROOM B1<BR>
<BR>
SESSION HEADING More on the co-morbidity of affective disorders and migraine<BR>
Chair: J Himmelhoch (USA)<BR>
<BR>
S-11-1 Merikangas, Kathleen R 
<BLOCKQUOTE>Familial Patterns of Comorbidity of Migraine and Mood Disorders</BLOCKQUOTE>
<BR>
S-11-2 Angst, Jules 
<BLOCKQUOTE>Affective Disorders and Headache Syndromes in the Community</BLOCKQUOTE>
<BR>
S-11-3 Akiskal, Hagop S 
<BLOCKQUOTE>Pleomorphic Expressions of Bipolarity</BLOCKQUOTE>
<BR>
<BR>
S-11-4 Ninan, Mathew T 
<BLOCKQUOTE>Valproate in Migraine Prophylaxis</BLOCKQUOTE>
<BR>
S-11-5 Himmelhoch, Jonathan M 
<BLOCKQUOTE>The Bipolar Nature of Migrainous Psychopathology</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM B2</B><BR>
<BR>
SESSION HEADING:Pharmacology of atypical neuroleptics in the elderly Chair:
D Jeste (USA)<BR>
<BR>
S-12-1 Jeste, Dilip V 
<BLOCKQUOTE>Typical Vs. Atypical Antipsychotics in Late-Life Psychosis</BLOCKQUOTE>
<BR>
S-12-2 Sweet, Robert A 
<BLOCKQUOTE>Atypical Neuroleptics: Pharmacologic Considerations</BLOCKQUOTE>
<BR>
S-12-3 Yamawaki, Shigeto 
<BLOCKQUOTE>Serotonin-Dopamine Antagonists in Elderly Schizophrenics</BLOCKQUOTE>
<BR>
S-12-4 Howard, Robert J 
<BLOCKQUOTE>Risperidone for Visual Hallucination in the Elderly</BLOCKQUOTE>
<BR>
S-12-5 Casey, Daniel E 
<BLOCKQUOTE>Atypical Neuroleptics in Older Monkeys</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM B4</B><BR>
<BR>
SESSION HEADING Behavioural and biochemical endpoints as indicators of developmental<BR>
effects of drugs of abuse<BR>
Chair: V Cuomo (Italy) Co-chair: F M Scalzo (USA)<BR>
<BR>
S-13-1 Alleva, Enrico 
<BLOCKQUOTE>Ontogeny of Behavioural Responses to Psychostimulants in Rodents</BLOCKQUOTE>
<BR>
S-13-2 Scalzo, Frank M 
<BLOCKQUOTE>The Role of NMDA Systems in theDevelopmental NeurobehaviouralToxicity
of of Phencyclidine</BLOCKQUOTE>
<BR>
S-13-3 Mereu, Giampaolo 
<BLOCKQUOTE>Neurophysiological Effects of Drugsof Abuse on Dopamine Neurons
In VitroDuring Development</BLOCKQUOTE>
<BR>
S-13-4 Schlumpf, Margret I 
<BLOCKQUOTE>Developmental Neuro - and Immunotoxicity of Benzodiazepines</BLOCKQUOTE>
<BR>
S-13-5 Cuomo, Vincenzo 
<BLOCKQUOTE>Neurobehavioural Changes Produced by Prenatal Exposure to Carbon
Monoxide,A Constituent of Cigarette Smoke</BLOCKQUOTE>
<HR><B>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM B3</B><BR>
<BR>
SESSION HEADING Molecular pathophysiology of Alzheimer's disease - Part
2<BR>
Chair: C Masters (Australia)<BR>
<BR>
S-14-1 Wesnes, K A 
<BLOCKQUOTE>Cholinergic Therapy Directed at Cognitive Deficits</BLOCKQUOTE>
<BR>
S-14-2 Kumar, R 
<BLOCKQUOTE>Muscarinic Partial Agonists in the Symptomatic Treatment of
Alzheimer's Disease</BLOCKQUOTE>
<BR>
S-14-3 Tasker, T 
<BLOCKQUOTE>Muscarinic Partial Agonists in theSymptomatic Treatment of Alzheimer'sDisease</BLOCKQUOTE>
<BR>
S-14-4 Robert, P H 
<BLOCKQUOTE>Therapeutic Strategies Directed at the Non-Cholinergic Transmitter
Systems</BLOCKQUOTE>
<BR>
S-14-5 Frostl, W 
<BLOCKQUOTE>GABA-B Receptors in Memory Processes</BLOCKQUOTE>
<BR>
<HR>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM B7<BR>
<BR>
SESSION HEADING Neuro AIDS II: diagnosis, neuropathology and emerging treatments<BR>
Chair: I Grant (USA) Co-chair: M Maj (Italy)<BR>
<BR>
S-15-1 Brew, Bruce J 
<BLOCKQUOTE>Cognitive Disorders in HIV Infection</BLOCKQUOTE>
<BR>
S-15-2 Everall, Ian P 
<BLOCKQUOTE>The Mechanisms and Clinical Relevance of HIV-AssociatedBrain
Damage</BLOCKQUOTE>
<BR>
S-15-3 Fein, George 
<BLOCKQUOTE>NMR Spectroscopy as a Tool for InVivo Detection and Monitoring
ofProgress of HIV CNS Disease</BLOCKQUOTE>
<BR>
S-15-4 Lyketsos, Constantine G 
<BLOCKQUOTE>The Epidemiology of Psychiatric Disorders in HIV Infection:Depression,
Mania and Dementia</BLOCKQUOTE>
<BR>
S-15-5 Treisman, Glenn J 
<BLOCKQUOTE>Treatment of Neuropsychiatric Disorders Associated With HIV
and AIDS</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM B5</B><BR>
<BR>
SESSION HEADING Growing points in the psychopharmacology of sleep<BR>
Chair: D Nutt (UK) Co-chair: E Holsboer-Trachsler (Switzerland)<BR>
<BR>
S-16-1 Steiger, Axel 
<BLOCKQUOTE>Neuropeptides in Human SleepRegulation</BLOCKQUOTE>
<BR>
S-16-2 Monti, Jaime M 
<BLOCKQUOTE>Benzodiazepines Versus Newer Hypnotics</BLOCKQUOTE>
<BR>
S-16-3 Holsboer-Trachsler, Edith 
<BLOCKQUOTE>GABA Mechanisms in Sleep Deprivation and Their Relevance to
Depression</BLOCKQUOTE>
<BR>
S-16-4 Berger, Mathias 
<BLOCKQUOTE>Cholinergic Mechanisms in Sleep and Depression</BLOCKQUOTE>
<BR>
S-16-5 Wilson, Sue 
<BLOCKQUOTE>SSRIs, TCAs and AugumentationTherapies - Exploring Mechanisms
By Acute and Chronic Sleep Effects</BLOCKQUOTE>
<HR><B>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM JB</B><BR>
<BR>
SESSION HEADING Broadening the spectrum of use for novel antipsychotics<BR>
Sponsored by Janssen-Cilag, Organon<BR>
Chair: G Remington (Canada) Co-chair: N Keks (Australia)<BR>
<BR>
S-17-1 Grebb, Jack 
<BLOCKQUOTE>Will Novel Antipsychotics be the Next Standard of Care for Patients
with Schizophrenia: a Worldwide Report on Risperidone</BLOCKQUOTE>
<BR>
S-17-2 Remington, Gary 
<BLOCKQUOTE>Medication Choices in Maintenance Neuroleptic Therapy: Theory
and Clinical Practice</BLOCKQUOTE>
<BR>
S-17-3 Aman, 
<BLOCKQUOTE>Title to be advised</BLOCKQUOTE>
<BR>
S-17-4 Keks, Nicholas A <BR>
<BR>
Clinical Experience of NovelAntipsychotics The Role of NovelAntipsychotics
for the Many Phases ofSchizophrenia<BR>
<BR>
S-17-5 Finar, 
<BLOCKQUOTE>Title to be advised</BLOCKQUOTE>
<BR>
S-17-6 Van Der Linden, 
<BLOCKQUOTE>Title to be advised</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1330-1600<BR>
<BR>
ROOM LA</B><BR>
<BR>
SESSION HEADING Circadian rhythms in neuropsychiatry and sleep disorders<BR>
Sponsored by Insitut De Recherches International Servier (I.R.I.S.)<BR>
Chair: S Armstrong (Australia) Co-chair: A Wirz-Justice (Switzerland)<BR>
<BR>
S-18-1 Turek, Fred W 
<BLOCKQUOTE>The Role of the Suprachiasmatic Nuclei (SCN) as a Biological
Clock:Effects of Melatoninergic Substances</BLOCKQUOTE>
<BR>
S-18-2 Redman, Jenny R 
<BLOCKQUOTE>Animal Models of Circadian Disorders and their Treatment with
Chronobiotics</BLOCKQUOTE>
<BR>
S-18-3 Wehr, Thomas A 
<BLOCKQUOTE>Sleep and Mood Disorders:Relationship to Circadian Rhythms</BLOCKQUOTE>
<BR>
S-18-4 Eastman, Charmane I 
<BLOCKQUOTE>Does Bright Light Treatment for Winter Depression Work Better
Than a Placebo?</BLOCKQUOTE>
<BR>
S-18-5 Lewy, Alfred J 
<BLOCKQUOTE>Circadian Phase Disorders and Psychiatry</BLOCKQUOTE>
<BR>
<HR><B>DAY Monday TIME 1600-1730<BR>
<BR>
ROOM C2-</B><BR>
<BR>
SESSION HEADING Poster Presentations<BR>
<BR>
P-1-1 McWilliam, Christopher 
<BLOCKQUOTE>Long Term Outcome of Fluoxetine Treatment in Elderly Depressed
Patients</BLOCKQUOTE>
<BR>
P-1-2 Wittgens, Wolfgang A 
<BLOCKQUOTE>Clinical Efficacy of Paroxetin in Old Age Depression</BLOCKQUOTE>
<BR>
P-1-3 Lauritzen, Lise 
<BLOCKQUOTE>Inter-Observer Reliability Among GPs in a Controlled Clinical
Study on Geriatric Depression</BLOCKQUOTE>
<BR>
P-1-4 Ko, Grant N 
<BLOCKQUOTE>Comparison of Sertraline and Fluoxetine in Depressed GeriatricOutpatients:
Plasma Levels and Efficacy</BLOCKQUOTE>
<BR>
P-1-5 Salokangas, Raimo K R 
<BLOCKQUOTE>Effect of Gender, Age and Smoking on Doses and Plasma Levels
of Neuroleptics in Schizophrenia</BLOCKQUOTE>
<BR>
P-1-6 Kamimura, Makoto 
<BLOCKQUOTE>Age Effect on the Plasma Levels of Various Psychotropic Drugs</BLOCKQUOTE>
<BR>
P-1-7 van Harten, Jaap 
<BLOCKQUOTE>Effect of Age, Gender and Food on the Pharmokinetics of Flesinoxan</BLOCKQUOTE>
<BR>
P-1-8 Ko, Grant N 
<BLOCKQUOTE>Sertraline and Nortriptyline: Heart Rate, Cognitive Improvement
and Quality of Life in Depressed Elderly</BLOCKQUOTE>
<BR>
P-1-9 Marazziti, Donatella 
<BLOCKQUOTE>No Age-Related Change in PlateletTritiated Paroxetine Binding
in Humans</BLOCKQUOTE>
<BR>
P-2-1 Jann, Michael W 
<BLOCKQUOTE>Lack of Pharmacokinetic Interaction Between Buspirone and Haloperidol
inSchizophrenic Patients</BLOCKQUOTE>
<BR>
P-2-2 Woo, Jong I 
<BLOCKQUOTE>Effect of Rifampin on Plasma Concentrations and Clinical Responses
of Haloperidol in Schizophrenics</BLOCKQUOTE>
<BR>
P-2-3 Avent, Kathryn M 
<BLOCKQUOTE>The Quantitative Analysis of a Haloperidol Derivative and Its
Neurotoxic Metabolites in Baboons</BLOCKQUOTE>
<BR>
P-2-4 McLennan, Holly R 
<BLOCKQUOTE>Mitochondrial Toxicity of Haloperidol and Its Metabolites</BLOCKQUOTE>
<BR>
P-2-5 Wong, James 
<BLOCKQUOTE>Multiple Dose Pharmacokinetics and Dose Proportionality Study
of 'Seroquel' (ICI 204, 636) in Male Schizophrenic Patients</BLOCKQUOTE>
<BR>
P-2-6 Muirhead, Gary 
<BLOCKQUOTE>The Effect of Ziprasidone on Steady-State Pharmacokinetics of
a Combined Oral Contraceptive</BLOCKQUOTE>
<BR>
P-2-7 Wilner, Keith 
<BLOCKQUOTE>Single and Multiple Dose Pharmocokinetics of Ziprasidone in</BLOCKQUOTE>
P-2-8 Wilner, Keith 
<BLOCKQUOTE>The Effects of Ziprasidone on Steady-State Lithium Levels and
Renal Clearance of Lithium</BLOCKQUOTE>
<BR>
P-2-9 Balant-Gorgia, Effie A 
<BLOCKQUOTE>Specific HPLC Method for Risperidone and 9-Hydroxy Risperidone
TherapeuticMonitoring</BLOCKQUOTE>
<BR>
P-2-10 Chang, Wen-Ho 
<BLOCKQUOTE>Reversible Metabolism of Clozapine and Clozapine N-oxide</BLOCKQUOTE>
<BR>
P-2-11 Van Gerven, Joop MA 
<BLOCKQUOTE>Kinetics/Dynamics of Midazolam and Two New Benzodiazepines During
First Administration in Man: I: RO 48-6791</BLOCKQUOTE>
<BR>
P-2-12 Van Gerven, Joop MA 
<BLOCKQUOTE>Kinetics/Dynamics of Midazolam and Two New Benzodiazepines During
First Administration in Man: II: RO 48-8684</BLOCKQUOTE>
<BR>
P-2-13 van Harten, Jaap 
<BLOCKQUOTE>Low Kinetic Interaction Potential of Flesinoxan in Man</BLOCKQUOTE>
<BR>
P-2-14 van Harten, Jaap 
<BLOCKQUOTE>No Kinetic or Dynamic Interaction Between Flesinoxan and Fluoxetine</BLOCKQUOTE>
<BR>
P-2-15 van Harten, Jaap 
<BLOCKQUOTE>The Influence of Morning and Evening Dosing on the Pharmokinetics
of Flesinoxan</BLOCKQUOTE>
<BR>
P-2-16 Franklin, Michael 
<BLOCKQUOTE>Sumatriptan in Plasma By HPLC with Coulometric Detection:Effect
of Paroxetine Treatment on Plasma Sumatriptan Concentrations</BLOCKQUOTE>
<BR>
P-2-17 Harvey, Annie 
<BLOCKQUOTE>Sertraline and P4503A3/4</BLOCKQUOTE>
<BR>
P-2-18 Wilner, Keith D 
<BLOCKQUOTE>Multiple Dose Pharmacokinetics of Sertraline in Subjects with
Varying Degrees of Hepatic Impairment</BLOCKQUOTE>
<BR>
P-2-19 Wilner, Keith D 
<BLOCKQUOTE>Multiple Dose Pharmacokinetics of Sertraline in Subjects with
Varying Degrees of Renal Impairment</BLOCKQUOTE>
<BR>
P-2-20 Kamijima, Kunitoshi 
<BLOCKQUOTE>Safety and Pharmacokinetics of Sertraline Hydrochloride in Japanese
Subjects</BLOCKQUOTE>
<BR>
P-2-21 Delbressine, Leon 
<BLOCKQUOTE>Pharmacokinetic Profile of Mirtazapine</BLOCKQUOTE>
<BR>
P-2-22 Stuppaeck, Christoph H 
<BLOCKQUOTE>Amitriptyline and Nortriptyline: Are Plasma Levels after First
DosePredictive for TherapeuticalEfficacy?</BLOCKQUOTE>
<BR>
P-2-23 Gorestein, Clarice 
<BLOCKQUOTE>Clomipramine and Obsessive-Compulsive Disorder: Serum Levels
and Outcome</BLOCKQUOTE>
<BR>
P-2-24 Marcourakis, Tania 
<BLOCKQUOTE>Clomipramine and Panic Disorder:Serum Levels and Clinical Improvement</BLOCKQUOTE>
<BR>
P-2-25 Lam, Y.W. Francis 
<BLOCKQUOTE>Selective Serotonin Reuptake Inhibitors (SSRI's) Concentration
andCYP2D6 Inhibition</BLOCKQUOTE>
<BR>
P-2-26 Harvey, A 
<BLOCKQUOTE>SSRIs and Inhibition of the Cytochrome P4502D6 Isoenzyme</BLOCKQUOTE>
<BR>
P-2-27 Baumann, Pierre 
<BLOCKQUOTE>Cytochrome P-450 Isozymes and N-Demethylation of Citalopram
Enantiomers in Vitro: Clinical Significance?</BLOCKQUOTE>
<BR>
P-2-28 Eap, Chin B 
<BLOCKQUOTE>Concentrations of the Enantiomers of Trimipramine and Its Metabolites
in CYP2D6 and CYP2C19 Phenotyped Patients</BLOCKQUOTE>
<BR>
P-2-29 Augustin, Bruce G 
<BLOCKQUOTE>Plasma Alpha-One Acid Glycoprotein (AAG) and Haloperidol (H)
Concentrations in Schizophrenic Patients</BLOCKQUOTE>
<BR>
P-3-1 Kono, Yoshihiro 
<BLOCKQUOTE>An Association Study Between the ADH2 Gene, the ALDH2 Gene and
Alcoholism</BLOCKQUOTE>
<BR>
P-3-2 Pitchot, William R 
<BLOCKQUOTE>5-HT 1A Receptors, Alcoholism and Suicidal Behaviour</BLOCKQUOTE>
<BR>
P-3-3 Huang, Chuong C 
<BLOCKQUOTE>Risperdal Reduces Alcohol Use in DualDisabled Schizophrenia
Patients</BLOCKQUOTE>
<BR>
P-3-4 Whitworth, Alexandra B 
<BLOCKQUOTE>Acamprosate in the Relapse Prevention of Alcohol Dependence</BLOCKQUOTE>
<BR>
P-3-5 Ida, Yoshishige 
<BLOCKQUOTE>Adrenal Gland Enlargement Resulting From Hyperactivity the Pituitary-Adrenocortical
System in Alcoholics</BLOCKQUOTE>
<BR>
P-3-6 Uchimura, Naohisa 
<BLOCKQUOTE>Treatment of Alcohol Withdrawal Delirium and Changes in Monoamine</BLOCKQUOTE>
<BR>
P-3-7 Mikolajczak, Przemyslaw 
<BLOCKQUOTE>Acamprosate Effect on Changes of Transferrin Levels in Ethanol
Preferring and Non-preferring Rats</BLOCKQUOTE>
<BR>
P-3-10 Bristow, Linda J 
<BLOCKQUOTE>Glycine/NMDA Antagonists Reduce Amphetamine Distruptions in
Prepulse Inhibition in the Rat</BLOCKQUOTE>
<BR>
P-3-11 Varavka, Sergei G 
<BLOCKQUOTE>Blockade of Brain Serotoninergic Receptors DeterioratesAmphetamine-Induced
Self-Stimulation in Rats With Lesions of Medial Prefrontal Cortex</BLOCKQUOTE>
<BR>
P-3-12 Tanaka, Tomoko 
<BLOCKQUOTE>Effects of Ritaserin on Methaphetamine-Induced Sensitization</BLOCKQUOTE>
<BR>
P-3-13 Shimizu, Yoshio 
<BLOCKQUOTE>Decrease in Calmodulin mRNA Level ofRat Hippocampus After Repeated
Methamphetamine Treatment</BLOCKQUOTE>
<BR>
P-3-14 Tung, Che-Se 
<BLOCKQUOTE>Effect of Behavioural Sensitization of Amphetamine On Schedule-
Induced Polydipsiasia (SIP) in Rats</BLOCKQUOTE>
<BR>
P-3-15 Parrott, Andrew C 
<BLOCKQUOTE>Ecstasy (MDMA): Mood Effects in Recreational Users</BLOCKQUOTE>
<BR>
P-3-16 Kelly, John P 
<BLOCKQUOTE>5-HT Uptake Inhibitors Attenuate the Neurochemical Effects of
3, 4 Methylenedioxymethamphetamine</BLOCKQUOTE>
<BR>
P-3-17 Hayashi, Teruo 
<BLOCKQUOTE>Chronic Treatment with Sulpiride Enhances NMDA-induced Ca2+
Influx in Cultured Rat Cortical Neurons</BLOCKQUOTE>
<BR>
P-3-18 Okulicz-Kozaryn, Irena 
<BLOCKQUOTE>Sedative Effect of Acamprosate and Its Influence on Chosen Memory
Tasks in Two Different Aged Rats</BLOCKQUOTE>
<BR>
P-4-1 Sitsen, Ad 
<BLOCKQUOTE>Mirtazapine vs TricyclicAntidepressants: An Overview ofEfficacy
Data</BLOCKQUOTE>
<BR>
P-4-2 Zivkov, Milana 
<BLOCKQUOTE>Mirtazapine vs Tricyclic Antidepressants in the Treatment of
Severely Depressed Patients</BLOCKQUOTE>
<BR>
P-4-3 Peyron, Eric 
<BLOCKQUOTE>Efficacay of Mirtazapine vs Clomipramine in Severely Depressed,
Hospitalized Patients</BLOCKQUOTE>
<BR>
P-4-4 Zivkov, Milana 
<BLOCKQUOTE>Safety of Mirtazapine in Overdose</BLOCKQUOTE>
<BR>
P-4-5 Zivkov, Milana 
<BLOCKQUOTE>Treatment With Mirtazapine is not<BR>
Related to Complaints of Sexual<BR>
Disfunction</BLOCKQUOTE>
<BR>
P-4-6 Kremer, Charlotte 
<BLOCKQUOTE>Mirtazapine Lacks Typical SSRI-Related Adverse Effects</BLOCKQUOTE>
<BR>
P-4-7 Kremer, Charlotte 
<BLOCKQUOTE>Efficacy of Mirtazapine in Moderate and Severe Depression</BLOCKQUOTE>
<BR>
P-4-8 Kremer, Charlotte 
<BLOCKQUOTE>Patterns of Mood Improvement With Mirtazapine</BLOCKQUOTE>
<BR>
P-4-9 Shrivastava, Ram K 
<BLOCKQUOTE>Nefazodone vs Sertraline in Outpatients with Major Depression:Effects
on Sexual Function</BLOCKQUOTE>
<BR>
P-4-10 Feighner, John P 
<BLOCKQUOTE>Efficacy of Nefazodone Versus Placebo in a Double-Blind Trial
of Depressed Impatients</BLOCKQUOTE>
<BR>
P-4-11 Matsubara, Ryoji 
<BLOCKQUOTE>A Double-Blind Comparison ofMilnacipran and Imipramine in Depressive
Patients</BLOCKQUOTE>
<BR>
P-4-12 Krsmanovic, Milorad T 
<BLOCKQUOTE>Comparitive Study of Moclobemide and Clomipramine in the Treatment
of Mild Forms of Depression</BLOCKQUOTE>
<BR>
P-4-13 Stankovic, Zana B 
<BLOCKQUOTE>Sulpiride Augmentation in Refractory Depression</BLOCKQUOTE>
<BR>
P-4-14 Timotijevic, Ivana P 
<BLOCKQUOTE>Efficacy of Combined Lithium/TCAs and Lithium/SSRIs Therapy
in Major Depressive Disorder</BLOCKQUOTE>
<BR>
P-4-15 Strauss, Wolfgang H 
<BLOCKQUOTE>Combined Cognitive-Behavioural and Pharmocotherapy in Refractory
Depression</BLOCKQUOTE>
<BR>
P-4-16 Fabre, Louis F 
<BLOCKQUOTE>Gepirone Extended Release (ER) Treatment of Outpatients with
Major Depression - A Dose Response Study</BLOCKQUOTE>
<BR>
P-4-17 Thakore, Jogin H Cortisol Synthesis Inhibition: A New<BR>
Treatment Strategy for Depression<BR>
<BR>
P-4-18 Yamamoto, Minoru 
<BLOCKQUOTE>Antidepressive Properties of Indeloxazine Hydrochloride, a Cerebral
Activator</BLOCKQUOTE>
<BR>
P-4-19 Ishigooka, Jun 
<BLOCKQUOTE>First Open Study with New Antidepressant LY248686 (Duloxetine)
for Depression in Japan</BLOCKQUOTE>
<BR>
P-4-20 Hirschfeld, Robert M 
<BLOCKQUOTE>Predictors of Outcome for Long-TermTreatment</BLOCKQUOTE>
<BR>
P-4-21 Steiner, Meir 
<BLOCKQUOTE>Serotonergic Dysregulation in Dysthmia</BLOCKQUOTE>
<BR>
P-4-22 Derivan, Albert T 
<BLOCKQUOTE>A Randomized, Double-Blind Placebo-Controlled Study: Venlafaxine
ER Capsules in Major Depression</BLOCKQUOTE>
<BR>
P-5-1 Tajima, Osamu 
<BLOCKQUOTE>Effects of Chronic Administration of Fluvozamine on Extracellular
Levels of Serotonin in the Rat Hippocampus in Vivo</BLOCKQUOTE>
<BR>
P-5-2 Pineyro, Graciela M 
<BLOCKQUOTE>Multiple 5-HT Receptor Subtypes Regulate 3H5-HT Release in TerminalProjection
Areas: Superfusion Studies in Rat and Mice Brain</BLOCKQUOTE>
<BR>
P-5-3 Curet, Olivier 
<BLOCKQUOTE>Effect of a Combination of Befloxatone and a 5HT1A Receptor
Antagonist on Rat Cortical Serotonin Release</BLOCKQUOTE>
<BR>
P-5-4 Mocaer, Elisabeth 
<BLOCKQUOTE>Anti-Agressive Effects of Alnespirone (S-20499), A Potent 5-HT1A
Receptor Agonist, in Wild-Type Rats</BLOCKQUOTE>
<BR>
P-5-5 Mocaer, Elisabeth 
<BLOCKQUOTE>Electrophysiological Effect ofAlnespirone (S-20499) On the Rat
Locus Coeruleus - Comparison With Buspirone</BLOCKQUOTE>
<BR>
P-5-6 Mocaer, Elisabeth 
<BLOCKQUOTE>Effects of Alnespirone (S 20499) in the Depression Model (Unavoidable
Aversive Light Stimulus Test) in Rats</BLOCKQUOTE>
<BR>
P-5-7 McGrath, Caroline J 
<BLOCKQUOTE>Effect of the Potential Anxiolytic Drug (+) S-20499 in the Olfactory
Bulbectomised Rat Model</BLOCKQUOTE>
<BR>
P-5-8 Leander, J. David 
<BLOCKQUOTE>Behavior-Enhancing Effects of 5H1A Agonists and 5HT2 Antagonists
on a Progressive Ratio Schedule</BLOCKQUOTE>
<BR>
P-5-9 Lane, Roger M 
<BLOCKQUOTE>Chirality and the SSRIs</BLOCKQUOTE>
<BR>
P-5-10 Broekkamp, Chris 
<BLOCKQUOTE>(+)-Mirtazapine and (+)-Desmethylmirtazapine Levels in Rat Brain
in Relation to in Vivo Blockade of Alpha2 Receptors</BLOCKQUOTE>
<BR>
P-5-11 Broekkamp, Chris 
<BLOCKQUOTE>Mirtazapine Stimulus Properties Reveal Indirect 5-HT1A Stimulus
Properties</BLOCKQUOTE>
<BR>
P-5-12 McGrath, Caroline J 
<BLOCKQUOTE>The Neurochemical and Behavioural Effects of the Isomers of
Mirtazapine in Normal Rats</BLOCKQUOTE>
<BR>
P-5-13 McGrath, Caroline J 
<BLOCKQUOTE>Effect of Chronic Antidepressant Treatment in the Olfactory
Bulbectomised Rat Model of Depression</BLOCKQUOTE>
<BR>
P-5-14 McGrath, Caroline J 
<BLOCKQUOTE>Effect of Nicotine Treatment, Pre And Post Surgery on the Behaviour
of the Olfactory Bulbectomised Rat</BLOCKQUOTE>
<BR>
P-5-15 Tadokoro, Chiyoko 
<BLOCKQUOTE>Sertraline Did Not Affect Monoamine Receptors and Adenylate
CyclaseActivity in Rat Brain</BLOCKQUOTE>
<BR>
P-5-16 Suzuki, Kaori 
<BLOCKQUOTE>Endogenous Mono-ADP-Ribosylation in the Hippocampus of Amygdaloid
Kindled Rat</BLOCKQUOTE>
<BR>
P-5-17 Grecksch, Gisela 
<BLOCKQUOTE>Importance of Protein Synthesis for the Development of Chemical
Kindling</BLOCKQUOTE>
<BR>
P-5-18 Kim, Young-Hoon 
<BLOCKQUOTE>Effects of Verapamil and Ethaverine on the Behavioural Despair
Test in Rats</BLOCKQUOTE>
<BR>
P-5-19 Jackson, Helen C 
<BLOCKQUOTE>Antidepressant-Like Effects of the I2 Ligands Idazoxan and 2-BFI
in the Rat Porsolt Test</BLOCKQUOTE>
<BR>
P-5-20 Miljevic, Cedo D 
<BLOCKQUOTE>L-Deprenyl Versus Moclobemide in Animal Model of Depression
- &quot;SwimTest&quot;</BLOCKQUOTE>
<BR>
P-5-21 Andrews, John 
<BLOCKQUOTE>Effects of Mirtazapine and Other Clinically Active Antidepressants
in the DRL-72</BLOCKQUOTE>
<BR>
P-5-22 Paunovic, Vladimir R 
<BLOCKQUOTE>Effects of Selective Antidepressants on the Sensitivity of Central
Adrenergic Receptors</BLOCKQUOTE>
<BR>
P-5-23 Maeda, Hideo 
<BLOCKQUOTE>Tricycles and SSRIS Enhance Adenylate Cyclase and cAMP-Related
Behaviours in Rat</BLOCKQUOTE>
<BR>
P-5-24 Baker, Glen B 
<BLOCKQUOTE>A Comparison of Phenelzine and its N-Acetylated Analogue in
the Elevated Plus-Maze Test</BLOCKQUOTE>
<BR>
P-5-25 Miyauchi, Tatsuo 
<BLOCKQUOTE>HT-90B A Putative Anxiolytic with Potent Antidepressive Activity</BLOCKQUOTE>
<BR>
P-5-26 Sluzewska, Anna M 
<BLOCKQUOTE>The Effect of Lithium Potentation of Antidepressants in Chronic
Mild Stress Model of Depression in Rats</BLOCKQUOTE>
<BR>
P-5-27 Walden, Jurg 
<BLOCKQUOTE>Increase of GABA-B Responses by Carbamazepine as a Mechanism
of Action in Affective Disorders</BLOCKQUOTE>
<BR>
P-6-1 Orgill, Anna A 
<BLOCKQUOTE>Behavioural and Cognitive Effects of Stimulant and Non Stimulant
Drugs in Childhood Attention Deficit Disorder</BLOCKQUOTE>
<BR>
P-6-2 Matsushima, Eisuke 
<BLOCKQUOTE>Exploratory Eye Movements in Child Patients with Mental Disorders</BLOCKQUOTE>
<BR>
P-6-3 Morosin, Alessandra 
<BLOCKQUOTE>Body Satisfaction in a Group of Obese Adolescents</BLOCKQUOTE>
<BR>
P-6-4 Ragazzoni, Paola 
<BLOCKQUOTE>Satisfaction With Life Anxiety and Eating Attitude in a Sample
of Obese Women</BLOCKQUOTE>
<BR>
P-6-5 Okamoto, Yuri 
<BLOCKQUOTE>Serotonin-Induced Platelet Calcium Response in Eating Disorders</BLOCKQUOTE>
<BR>
P-6-6 Evans, Suzette M 
<BLOCKQUOTE>Menstrual Cycle Effects in Women with Premenstrual Syndrome</BLOCKQUOTE>
<BR>
P-6-7 Obillo, Edna Elaine M 
<BLOCKQUOTE>Maprotiline For Depresssion During Menopause: A Philippine Menopause
Clinic Experience</BLOCKQUOTE>
<BR>
P-6-8 Steiner, Meir 
<BLOCKQUOTE>Cortisol and Maternal Attraction to Infant Odour</BLOCKQUOTE>
<BR>
P-6-9 Blankley, Gaynor R 
<BLOCKQUOTE>Establishing a Liaison Network forPostnatal Depression in the
Primary Care Setting</BLOCKQUOTE>
<BR>
P-7-1 Tollefson, Gary D 
<BLOCKQUOTE>The Course of Primary and Secondary Negative Symptoms in a Controlled
Trial with Olanzapine</BLOCKQUOTE>
<BR>
P-7-2 Tran, Pierre V 
<BLOCKQUOTE>Olanzapine Versus Placebo, Results of the United-States Double-Blind
Olanzapine Trial</BLOCKQUOTE>
<BR>
P-7-3 Tran, Pierre V 
<BLOCKQUOTE>Acute and Long-Term Results of theDose Ranging Double-Blind
Olanzapine Trial</BLOCKQUOTE>
<BR>
P-7-4 Tran, Pierre V 
<BLOCKQUOTE>Acute and Long-Term Results of the North American Double-Blind
Olanzapine Trial</BLOCKQUOTE>
<BR>
P-7-5 Tran, Pierre V 
<BLOCKQUOTE>Olanzapine Versus Haloperidol: Acute Results of the Multi- Center
International Trial</BLOCKQUOTE>
<BR>
P-7-6 Tran, Pierre V 
<BLOCKQUOTE>Olanzapine Versus Haloperidol: Long-Term Results of the Multi-
Center International Trial</BLOCKQUOTE>
<BR>
P-7-7 Ishigooka, Jun 
<BLOCKQUOTE>Clinical Efficacy and Safety of Olanzapine in Japanese Schizophrenics</BLOCKQUOTE>
<BR>
P-7-8 Dilbaz, Nesrin H 
<BLOCKQUOTE>The Efficacy of Zuclopenthixol Acetate in the Treatment of Psychotic
Patients</BLOCKQUOTE>
<BR>
P-7-9 Galeno, Roxana B 
<BLOCKQUOTE>Clinical Experience with Zuclopentixol in 25 Acute Schizophrenic
Patients</BLOCKQUOTE>
<BR>
P-7-10 Berk, Michael <BR>
A Controlled Double Blind Study of Zuclopenthixol Acetate Compared with
Clothiapine in Acute Psychosis Including Mania and Exacerbation of Chronic
Psychosis<BR>
<BR>
P-7-11 Guazzelli, Mario 
<BLOCKQUOTE>Efficacy of 1-Sulpiride in the Treatment of Disorganization
in Acutely Relapsed Schizophrenics</BLOCKQUOTE>
<BR>
P-7-12 Turjanski, Silvia N 
<BLOCKQUOTE>Amisulpride in the treatment of Acute Schizophrenia: a Double-Blind
Comparison with Haloperidol</BLOCKQUOTE>
<BR>
P-7-13 Turjanski, Silvia N 
<BLOCKQUOTE>Amisulpride in the Treatment of Acute Episodes of Schizophrenia</BLOCKQUOTE>
<BR>
P-7-14 Tamminga, Carol A 
<BLOCKQUOTE>Efficacy and Safety of Three Doses of Sertindole and Haldol
in Schizophrenic Patients</BLOCKQUOTE>
<BR>
P-7-15 van der Burght, Michael 
<BLOCKQUOTE>Dose Ranging Study Comparing 4 Doses of Sertindole and 1 Dose
of Haloperidol in Schizophrenic Patients</BLOCKQUOTE>
<BR>
P-7-16 Daniel, David G 
<BLOCKQUOTE>Two Open-Label Long-Term Safety Studies of Sertindole</BLOCKQUOTE>
<BR>
P-7-17 Sachdev, Perminder 
<BLOCKQUOTE>The &quot;Organic&quot; Basis of Late-OnsetSchizophrenia</BLOCKQUOTE>
<BR>
P-7-18 Tollefson, Gary D 
<BLOCKQUOTE>Comorbid Mood Disturbance in Schizophrenia</BLOCKQUOTE>
<BR>
P-7-19 Boyer, Patrice 
<BLOCKQUOTE>Anhedonia and Depression in Chronic Schizophrenia</BLOCKQUOTE>
<BR>
P-7-20 Addington, Donald E 
<BLOCKQUOTE>The Relationship Between Negative Symptoms and Depression in
Schizophrenia</BLOCKQUOTE>
<BR>
P-7-21 Maltez, Jorge 
<BLOCKQUOTE>Negative Symptom and Neuropsychologic Dysfunction are Independent
Features of Schizophrenias</BLOCKQUOTE>
<BR>
P-7-22 Higuchi, Hisashi 
<BLOCKQUOTE>Panic Attacks in Chronic Schizophrenia - A Complication of Long-Term
Antipsychotic Medication</BLOCKQUOTE>
<BR>
P-7-23 Shriqui, Christian L 
<BLOCKQUOTE>Clozapine in Treatment-Resistant Schizophrenic Patients: Clinical,
Neuropsychological and Neuroanatomical Correlates of Outcome</BLOCKQUOTE>
<BR>
P-7-24 Tanabe, Eiichi 
<BLOCKQUOTE>Correlations Between Neurophysiological Abnormalities and Brain
Morphological Changes in Schizophrenia</BLOCKQUOTE>
<BR>
P-7-25 Danion, Jean-Marie JM 
<BLOCKQUOTE>Impairment of Spatial Context Memory in Schizophrenia</BLOCKQUOTE>
<BR>
P-7-26 Xia, Mei-Lan 
<BLOCKQUOTE>Eye Movement Studies on Schizophrenics and their Parents</BLOCKQUOTE>
<BR>
P-7-27 Ando, Harunobu 
<BLOCKQUOTE>Eye Movements Made During the Performance of a Maze Test in
Schizophrenic Patients</BLOCKQUOTE>
<BR>
P-7-28 Lindstrom, Eva M 
<BLOCKQUOTE>A Checklist for Assessment of Treatment in Schizophrenic Syndromes:
Interscale Validity and Interrater Reliability</BLOCKQUOTE>
<BR>
P-7-29 Inada, Toshiya 
<BLOCKQUOTE>Inter-rater Reliability of the Drug-Induced Extrapyramidal Symptoms
Scale (DIEPSS)</BLOCKQUOTE>
<BR>
P-7-30 Robert, Phillippe H 
<BLOCKQUOTE>Neurocognitive Subtypes of Schizophrenia. According to Performances
at the Verbal Fluency Test</BLOCKQUOTE>
<BR>
P-7-31 Hawley, Chris J 
<BLOCKQUOTE>The Attribution of Intentionality, Casuality and Disposition
By Deluded Patients</BLOCKQUOTE>
<BR>
P-7-32 Flyckt, Lena 
<BLOCKQUOTE>An Inventory of Chronic, Mentally Disabled Schizophrenic Outpatients</BLOCKQUOTE>
<BR>
P-7-33 Tan, Chay-Hoon 
<BLOCKQUOTE>Serotonin in Platelets and Whole Blood in Schizophrenic Patients</BLOCKQUOTE>
<BR>
P-7-34 de Oliveira, Irismar R 
<BLOCKQUOTE>Risperidone Vs Haloperidol in the Treatment of Schizophrenia:
A Meta-Analysis Comparing Their Efficacy and Safety</BLOCKQUOTE>
<BR>
<HR>
<P><CENTER><A HREF="index.htm#anchor689408"><IMG SRC="files.gif/smanlog.gif"
WIDTH="62" HEIGHT="57" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></A></CENTER>
</BODY>
</HTML>
</DOC>